UK markets closed

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
8.52-0.16 (-1.84%)
As of 02:10PM EDT. Market open.
Sign in to post a message.
  • E
    E
    Cara disclosed March monthly sales. Per Cara, dialysis centers don't store tons of inventory and they use single dose vials. I estimate the March sales at roughly $5m or 2,800 patients, a fraction of the addressable US market of 150-200K. Dialysis is 3x/week or 12x over a 4 week month at $150/vial, equivalent to $1,800/patient/month. 50,000 patient months is equivalent to $270 million per quarter of which Cara receives 50%.
  • M
    Michael
    Pfizer just bought Biohaven. My shares are up 68% today! It's my third biotech buyout...and CARA will next.
  • R
    Roi
    cryptocurrency does not fly like our Cara ... the share of institutional ownership has been increased from 58 to 61%
  • S
    Stan
    Cara filed $300M shelf registration today. I've been using 85-90M shares outstanding and 8 PE and implied price is still above $25
  • M
    Michael
    It truly is a baffling stock to own and follow. I guess we will see once the revenue numbers start to come in -- I share the pain with all the longs -- but I still believe that this stock will soar some time soon.
  • b
    bruce
    OK, ...It's time for the first of two sudo-scientific Kosuva sales and marketing survey. The actual test involved an actual visit to a Fresenius Clinic. Now before you think this was a big deal, I must point out that this clinic was across the street from a Harbor Freight store in Nashville. I had a number of questions, the first being was how Korsuva was doing? Was it effective? and, Did the patients like it? The answer, and this came from two clinic workers, was .....We Never Heard of it, have never used it, and what does it do again? So....maybe, just maybe, that is why we are getting NO sales and application results. I mentioned this is the first of a two part survey. The second part will take place on Monday. I have the number of the Fresenius regional office and will call them then.
    Something is amiss here. Posner said inventory was in the distributors stock before Ap. 1, 22, why has it not been sent to the clinics. I had a theory, previously posted, about Vifor/CSL having issues with Fresenius over pricing and discounts. Could this be actually happening. As always, I am prepared to be proven wrong.
  • S
    Samantha
    I am so tired of CARA doing nothing all day. Can you move??? I have been reading (http://Achieverspot.tech) for a month now and the stocks there actually go!
  • C
    Chris
    So following up on Bruces posting from a couple of days ago I also called someone I know who works in a Fresenius clinic in San Diego. He works with patients who are doing at home dialysis but has not heard of this drug or been asked to use it with his patients. One must assume that these technicians will be trained how to administer this IV drug before being cleared to administer it so I think it's going to be a while before anyone see's any revenue from this application.
  • l
    leon
    A good earning report is coming.
  • J
    Jeffrey
    My last thought for today
    To all the longs - if this stock ever really takes off us long term investors will deserve every dollar we get
  • C
    Chris
    Here we are rolling almost into May and still no news on pricing. No news on when the IV drug will be rolled out in clinics. No news on EU approval. No news on Oral phase 2 which was supposed to be wrapped up and results released in the 1st quarter and no news really on anything else but I expect the Hedge Funds and Major Institutions get weekly updates.
  • D
    Douglas
    Take a look at the chart of XBI (SPDR S&P Biotech) and you will see one of our problems that has nothing to do with CARA
  • M
    Mitchell
    Cara Therapeutics GAAP EPS of -$0.52 beats by $0.10, revenue of $4.79M beats by $2.53M.
  • M
    Michael
    It seems like they are getting Korsuva into solid distribution and focusing 100 Vifor reps on selling the drug within its own system. It's normal for a lag as a medication hits the ground. Early adoptors jump in first. Then it grows from there. I think the revenue is good for this stage and will get better a reps realize they need to push it to make quota. By push it, I mean simply spread the word and share the research first... Anything New is a rep's dream. This is lots of new.
  • S
    Stan
    Follow-up to Chris / Bruce inquiries into the Fresenius awareness and use of Korsuva. I too checked around (NYC area). The dialysis center doctors at a large NYC hospital system have heard of Korsuva injection but have not yet administered to patients.
  • R
    Roi
    Friends, super cool profitable companies have fallen by 15-30 percent in a month, why then should Cara grow?
  • 8
    8,891,000 views
    $10 call options are still cheap already up %80 come on bulls easy money lets get this money also dont forget to buy shares and most importantly HOLD
  • r
    roberta
    Sorry but there is absolutely no excuse for the lack of communication from management. It shows a total contempt for share holders which boarders on criminal. If there is a class action count me in.
  • G
    Gh
    EU approval of kapruvia will net $15M milestone payment for 2Q22 per the CFO during the Needham call.
  • 8
    8,891,000 views
    This breaks 9.25 and we're headed for the $10.40s+++